相关实验视频

Updated: Sep 10, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

针对不同型号的人类肺腺癌的一种新型基因酸基DC25酸酶抑制剂

Tsung-Ching Lai¹, Iin Narwanti², Bidyadhar Sethy³

¹Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Pulmonary Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|August 21, 2025

概括

新型化合物6有效抑制CDC25酸酶,对肺腺癌 (LUAD) 有强大的抗癌作用. 在临床前模型中,这种CDC25抑制剂通过抑制瘤生长和增强化疗效来显示治疗潜力.

科学领域:

癌症学
分子生物学
药物发现

背景情况:

细胞分裂周期25 (CDC25) 酸酶是关键的细胞周期调节剂,与瘤恶性有关.
CDC25的过度表达与预后不佳相关,使得CDC25成为癌症的重要治疗点.
抑制CDC25抑制癌细胞的增殖并诱导细胞亡,这突显了其治疗意义.

研究的目的:

开发具有潜在治疗应用的新型CDC25抑制剂.
在肺癌模型中评估合成的CDC25抑制剂,特别是化合物6.
在肺腺癌 (LUAD) 患者数据中调查CDC25表达的临床相关性.

主要方法:

基于化合物NSC663284 (化合物1) 的CDC25抑制剂衍生物的合成和选.
使用细胞活力测定,体外功能测定 (细胞毒性,细胞亡,殖民地形成,迁移,入侵) 和体内异种移植小鼠模型评估化合物的疗效.
来自CPTAC和TCGA-LUAD数据集的临床数据分析,以将CDC25表达与预后和临床病理特征相关联.

主要成果:

与化合物1相比,化合物6表现出强烈的CDC25酸酶抑制活性和更高的细胞毒性和亲亡作用.
临床数据分析显示,高的CDC25A和CDC25C表达与LUAD的预后不佳和晚期瘤阶段有关.
化合物6显著抑制了LUAD细胞的生长,迁移,侵袭和异种移植瘤的进展,并与化疗产生了协同作用.

结论:

化合物6是对CDC25抑制的一种非常有前途的化合物.
化合物6在体外和体内表现出显著的抗瘤活性,包括患者衍生器官.
需要对化合物6进行进一步的研究,以确定其作为肺腺癌治疗剂的潜力.

关键词:

细胞亡酸酶抑制剂肺腺癌肺腺癌来自患者的有机物形结构

更多相关视频

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...